RESUMEN
Recently, the effectiveness of renal sympathetic nerve denervation for treatment of hypertension has been doubted after SYMPLICITY HTN-3 trial. An ideal animal model is still unavailable for preclinical study about catheter-based renal sympathetic nerve denervation for treatment of hypertension. Traditional high-dose deoxycorticosterone acetate (DOCA)-induced hypertension pig model has some problems due to extensive end-organ damage. Based on the similarity in the anatomic characteristics of renal artery between pigs and humans, this study was undertaken to establish a low-dose sustained-release DOCA-induced hypertension model in pigs. A total of 14 pigs were subcutaneously implanted with low-dose DOCA in the abdomen and cannulated from the femoral artery for the measurement of blood pressure (BP). Plasma angiotensin I (Ang I), angiotensin II (Ang II), plasma renin activity (PRA), aldosterone (Ald), creatinine, epinephrine, and norepinephrine (NE) were determined before and after treatments. The kidneys were collected and processed for hematoxylin and eosin staining, Masson-Goldner trichromic, and periodic acid Schiff staining. Ten pigs survived for 1 month. Mean BP significantly increased after 2-week treatment (P < .001). The plasma Ang I, Ang II, PRA, and Ald significantly decreased (Ang I: 6.92 ± 6.06 vs. 2.22 ± 3.08, P = .002; Ang II: 768.85 ± 525.8 vs. 213.76 ± 148.63, P = .003; PRA: 1.68 ± 1.67 vs. 0.29 ± 0.39, P = .008; Ald: 0.37 ± 0.12 vs. 0.25 ± 0.09, P < .001), but norepinephrine significantly increased (7.59 ± 4.57 vs. 16.96 ± 10.38, P = .021). Plasma creatinine remained unchanged. Hisotological examination showed mild damage to the kidney. Low-dose sustained-release DOCA is able to induce hypertension in pigs. A femoral catheter is not only helpful for monitoring BP, but can be used to quickly exchange the renal sympathetic nerve denervation equipment.
Asunto(s)
Modelos Animales de Enfermedad , Hipertensión/cirugía , Riñón/inervación , Mineralocorticoides/farmacología , Porcinos Enanos/fisiología , Simpatectomía , Animales , Presión Sanguínea/efectos de los fármacos , Determinación de la Presión Sanguínea/métodos , Catéteres , Preparaciones de Acción Retardada/farmacología , Desoxicorticosterona/farmacología , Relación Dosis-Respuesta a Droga , Implantes de Medicamentos/farmacología , Arteria Femoral/cirugía , Humanos , Hipertensión/sangre , Hipertensión/inducido químicamente , Riñón/patología , Pruebas de Función Renal , Masculino , Sistema Renina-Angiotensina/efectos de los fármacos , PorcinosRESUMEN
The aim of this study was to develop mucoadhesive pellets on a thiolated pectin base using the extrusion-spheronization technique. Thiolation of pectin was performed by esterification with thioglycolic acid. The molecular weight and thiol group content of the pectins were determined. Pellets containing pectin, microcrystalline cellulose, and ketoprofen were prepared and their mucoadhesive properties were evaluated through a wash-off test using porcine intestinal mucosa. The in vitro ketoprofen release was also evaluated. Thiolated pectin presented a thiol group content of 0.69 mmol/g. Thiolation caused a 13% increase in polymer molecular weight. Pellets containing thiolated pectin were still adhering to the intestinal mucosa after 480 min and showed a more gradual release of ketoprofen. Conversely, pellets prepared with nonthiolated pectin showed rapid disintegration and detached after only 15 min. It can be concluded that thiolated pectin-based pellets can be considered a potential platform for the development of mucoadhesive drug delivery systems for the oral route.
Asunto(s)
Adhesivos/síntesis química , Química Farmacéutica/métodos , Implantes de Medicamentos/síntesis química , Compuestos de Sulfhidrilo/síntesis química , Adhesivos/metabolismo , Adhesivos/farmacología , Animales , Implantes de Medicamentos/metabolismo , Implantes de Medicamentos/farmacología , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Pectinas , Compuestos de Sulfhidrilo/metabolismo , Compuestos de Sulfhidrilo/farmacología , PorcinosRESUMEN
In the absence of adequate oxygen, cancer cells that are grown in hypoxic solid tumors resist treatment using antitumor drugs (such as doxorubicin, DOX), owing to their attenuated intracellular production of reactive oxygen species (ROS). Hyperbaric oxygen (HBO) therapy favorably improves oxygen transport to the hypoxic tumor tissues, thereby increasing the sensitivity of tumor cells to DOX. However, the use of HBO with DOX potentiates the ROS-mediated cytotoxicity of the drug toward normal tissues. In this work, we hypothesize that regional oxygen treatment by an implanted oxygen-generating depot may enhance the cytotoxicity of DOX against malignant tissues in a highly site-specific manner, without raising systemic oxygen levels. Upon implantation close to the tumor, the oxygen-generating depot reacts with the interstitial medium to produce oxygen in situ, effectively shrinking the hypoxic regions in the tumor tissues. Increasing the local availability of oxygen causes the cytotoxicity of DOX that is accumulated in the tumors to be significantly enhanced by the elevated production of ROS, ultimately allaying the hypoxia-induced DOX resistance in solid malignancies. Importantly, this enhancement of cytotoxicity is limited to the site of the tumors, and this feature of the system that is proposed herein is unique.
Asunto(s)
Antineoplásicos/farmacología , Doxorrubicina/farmacología , Implantes de Medicamentos/farmacología , Oxigenoterapia Hiperbárica/métodos , Hipoxia Tumoral/efectos de los fármacos , Animales , Antígenos de Neoplasias/metabolismo , Cloruro de Calcio/química , Anhidrasa Carbónica IX/metabolismo , Catalasa/química , Catalasa/metabolismo , Línea Celular Tumoral , Doxorrubicina/farmacocinética , Implantes de Medicamentos/química , Resistencia a Antineoplásicos/efectos de los fármacos , Humanos , Ratones Desnudos , Oxígeno , Peróxidos/química , Tomografía de Emisión de Positrones , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Magnetic hyperthermia ablation is a new and minimally invasive modality for localized tumor removal. However, an inadequate ablation dosage can leave a residual tumor or cause a variety of complications. In addition, commonly used magnetic nanoparticles can easily escape from the tumor tissue, which present potential safety problems. In this study, a smart phase transitional and injectable implant based on biocompatible poly lactic-co-glycolic acid (PLGA) implant incorporating magnetic material (Fe powder) and anti-cancer drug (doxorubicin (DOX)) was developed. The magnetic-induced hyperthermia and release efficiency of DOX were evaluated in vitro. Drug release can be controlled under external alternating current magnetic field (AMF). The results of the in vivo tumor therapeutic efficacy showed that when exposed to external AMF, this smart injectable DOX/PLGA-Fe implant could converse magnetic energy into heat and accelerate the release of DOX, which leads to increasing the temperature to achieve tumor coagulative necrosis and accelerating the release of DOX to enhance residual tumor apoptosis. Furthermore, there was no leakage of magnetic material, as demonstrated using real-time ultrasound (US) and computerized tomography (CT) imaging, realizing the guidance and monitoring of tumor therapy. In conclusion, this smart phase transitional and injectable implant DOX/PLGA-Fe has the ability to improve the efficiency of this newly developed minimally invasive magnetic ablation of tumor treatment technique, and will provide a new avenue of developing minimally invasive synergistic tumor therapy.
Asunto(s)
Doxorrubicina , Implantes de Medicamentos , Hipertermia Inducida , Hierro , Ácido Láctico , Campos Magnéticos , Neoplasias Experimentales/terapia , Ácido Poliglicólico , Animales , Bovinos , Línea Celular Tumoral , Doxorrubicina/química , Doxorrubicina/farmacocinética , Doxorrubicina/farmacología , Implantes de Medicamentos/química , Implantes de Medicamentos/farmacocinética , Implantes de Medicamentos/farmacología , Humanos , Hierro/química , Hierro/farmacocinética , Hierro/farmacología , Ácido Láctico/química , Ácido Láctico/farmacocinética , Ácido Láctico/farmacología , Ratones , Ácido Poliglicólico/química , Ácido Poliglicólico/farmacocinética , Ácido Poliglicólico/farmacología , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
There is growing interest in biomaterials that can cure bone infection and also regenerate bone. In this study, two groups of implants composed of 10% (wt/wt) teicoplanin (TEC)-loaded borate bioactive glass (designated TBG) or calcium sulfate (TCS) were created and evaluated for their ability to release TEC in vitro and to cure methicillin-resistant Staphylococcus aureus (MRSA)-induced osteomyelitis in a rabbit model. When immersed in phosphate-buffered saline (PBS), both groups of implants provided a sustained release of TEC at a therapeutic level for up to 3 to 4 weeks while they were gradually degraded and converted to hydroxyapatite. The TBG implants showed a longer duration of TEC release and better retention of strength as a function of immersion time in PBS. Infected rabbit tibiae were treated by debridement, followed by implantation of TBG or TCS pellets or intravenous injection with TEC, or were left untreated. Evaluation at 6 weeks postimplantation showed that the animals implanted with TBG or TCS pellets had significantly lower radiological and histological scores, lower rates of MRSA-positive cultures, and lower bacterial loads than those preoperatively and those of animals treated intravenously. The level of bone regeneration was also higher in the defects treated with the TBG pellets. The results showed that local TEC delivery was more effective than intravenous administration for the treatment of MRSA-induced osteomyelitis. Borate glass has the advantages of better mechanical strength, more desirable kinetics of release of TEC, and a higher osteogenic capacity and thus could be an effective alternative to calcium sulfate for local delivery of TEC.
Asunto(s)
Compuestos de Boro/farmacología , Sulfato de Calcio/farmacología , Portadores de Fármacos/farmacología , Implantes de Medicamentos/farmacología , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Osteomielitis/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Animales , Antibacterianos/farmacología , Compuestos de Boro/química , Sulfato de Calcio/química , Modelos Animales de Enfermedad , Portadores de Fármacos/síntesis química , Implantes de Medicamentos/síntesis química , Durapatita/química , Femenino , Vidrio/química , Inyecciones Intralesiones , Staphylococcus aureus Resistente a Meticilina/crecimiento & desarrollo , Osteomielitis/microbiología , Osteomielitis/patología , Conejos , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/patología , Teicoplanina/farmacología , Tibia/efectos de los fármacos , Tibia/microbiología , Tibia/patología , Resultado del TratamientoRESUMEN
Repaglinide, an oral antidiabetic agent, has a rapid onset of action and short half-life of approximately 1 h. Designing a controlled release dosage form of the drug is required to maintain its therapeutic blood level and to eliminate its adverse effects, particularly the hypoglycaemia. Repaglinide sustained release matrix pellets consisting of Avicel, lactose and different polymers were prepared using extrusion-spheronisation method. The effect of different formulation components on in vitro drug release were evaluated using USP apparatus (paddle) for 12 h in phosphate buffer. The optimised formulation was orally administrated to normal and STZ induced diabetic rats. Most pellet formulations had acceptable physical properties with regard to size distribution, flowability and friability. Repaglinide pellets comprising Avicel 50%, lactose 47% and SLS 1% were released 94% of its drug content after 12 h. The optimised formulation was able to decrease blood glucose level in normal rats and those with diabetes throughout 8-12 h.
Asunto(s)
Carbamatos , Diabetes Mellitus Experimental/tratamiento farmacológico , Hipoglucemiantes , Piperidinas , Administración Oral , Animales , Glucemia/metabolismo , Carbamatos/química , Carbamatos/farmacocinética , Carbamatos/farmacología , Celulosa/química , Diabetes Mellitus Experimental/sangre , Evaluación Preclínica de Medicamentos , Implantes de Medicamentos/farmacocinética , Implantes de Medicamentos/farmacología , Hipoglucemiantes/química , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Lactosa/química , Masculino , Piperidinas/química , Piperidinas/farmacocinética , Piperidinas/farmacología , Ratas , Ratas WistarRESUMEN
The effect of ractopamine hydrochloride (RH) and zilpaterol hydrochloride (ZH) on slice shear force (SSF) and sensory characteristics of beef from calf-fed Holstein steers was evaluated. All steers were implanted with a progesterone (100 mg) plus estradiol benzoate (10 mg) implant followed by a terminal trenbolone acetate (200 mg) plus estradiol (40 mg) implant. Steers were blocked by weight into pens (n = 32) randomly assigned to 1 of 4 treatments: control, RH fed at 300 mg·steer(-1)·d(-1) (RH 300) or RH fed at 400 mg·steer(-1)·d(-1)(RH 400) for the final 31 d of finishing, or ZH fed at 6.8 g/t for 21 d with a 5-d withdrawal before harvest. Fourteen carcasses were randomly selected from each pen, and two LM samples (1 per side) were excised and aged either 14 or 21 d before SSF testing. For trained panel evaluation, two steaks were collected from each of 60 low Choice strip loins (20 each from control, RH 300, and ZH treatments) and aged either 14 or 21 d. Steers fed RH and ZH produced steaks with SSF values that were 9% to 25% higher than controls. No difference in SSF was detected between the two levels of RH (P > 0.05). Compared to controls, the probability of steaks aged 14 d failing to meet SSF requirements to be certified tender (SSF < 20 kg) was increased 0.15, 0.17, and 0.26 in steers fed RH 300, RH 400, and ZH, respectively. Compared to controls, the probability of steaks aged 21 d having SSF values >20 kg was increased 0.03, 0.08, and 0.16 in steers fed RH 300, RH 400, and ZH, respectively. Steaks from Select carcasses of steers fed ZH aged 21 d postmortem had double the probability (0.39 vs. 0.17) of having SSF values >20 kg compared to steaks from steers fed either level of RH (P < 0.05). This difference tended to be identical in steaks from Select carcasses 14 d postmortem (0.50 vs. 0.33; P = 0.11); however, no difference was found in low Choice samples at 14 or 21 d postmortem. Trained panelists rated steaks aged 14 d from steers fed ZH lower for overall tenderness and flavor compared to controls (P < 0.05); however, no difference was found between controls and those fed RH 300. Steaks from steers fed ZH aged 21 d were rated lower for overall tenderness and juiciness compared to controls and those from steers fed RH 300 (P < 0.05). This study suggests RH and ZH negatively impact sensory attributes of beef from calf-fed Holstein steers.
Asunto(s)
Agonistas Adrenérgicos beta/metabolismo , Composición Corporal/efectos de los fármacos , Bovinos/fisiología , Carne/análisis , Músculos Paraespinales/efectos de los fármacos , Fenetilaminas/metabolismo , Compuestos de Trimetilsililo/metabolismo , Agonistas Adrenérgicos beta/administración & dosificación , Alimentación Animal/análisis , Animales , Dieta/veterinaria , Suplementos Dietéticos/análisis , Implantes de Medicamentos/administración & dosificación , Implantes de Medicamentos/farmacología , Estradiol/administración & dosificación , Estradiol/análogos & derivados , Estradiol/farmacología , Masculino , Músculos Paraespinales/fisiología , Fenetilaminas/administración & dosificación , Progesterona/administración & dosificación , Progesterona/farmacología , Resistencia al Corte , Acetato de Trembolona/administración & dosificación , Acetato de Trembolona/farmacología , Compuestos de Trimetilsililo/administración & dosificaciónRESUMEN
Effects of ractopamine hydrochloride (RH) and zilpaterol hydrochloride (ZH) on saleable yield of carcass sides from calf-fed Holstein steers were evaluated using steers implanted with a progesterone (100 mg) plus estradiol benzoate (10 mg) implant followed by a terminal trenbolone acetate (200 mg) plus estradiol (40 mg) implant. Steers were blocked by weight into pens (n = 32) randomly assigned to one of four treatments: control, RH fed at 300 mgâ¢steer(-1)/d(-1) (RH 300) or RH fed at 400 mgâ¢steer(-1)/d(-1) (RH 400) the final 31 d of finishing, and ZH fed at 60 to 90 mgâ¢steer(-1)/d(-1) (7.56 g/ton on a 100% DM basis) for 21 d with a 5 d withdrawal before harvest. Eight to nine carcass sides were randomly selected from each pen; carcass sides with excessive hide pulls, fat pulls or bruises were avoided. Cutout data were collected within a commercial facility using plant personnel to fabricate sides at a rate of one every 3 to 4 min into items typically merchandised by the facility. All lean, fat and bone were weighed and summed back to total chilled side weight with a sensitivity of ± 2% to be included in the data set. Compared to controls, ß-agonists increased saleable yield of whole-muscle cuts by 0.61%, 0.86% and 1.95% for RH 300, RH 400 and ZH, respectively (P < 0.05). Percent fat was less in carcasses from the ZH treatment compared to controls (P < 0.05); however, this difference was not observed between RH treatments and controls (P > 0.05). Percent bone was less in the ZH treatment due to increased muscle (P < 0.05). The percent of chilled side weight comprised of trimmings was unchanged between treatments, but on a 100% lean basis, RH 400 and ZH increased trim yields (P < 0.05). Analysis of saleable yield by primal showed a fundamental shift in growth and development. Beta-agonists caused a shift in proportion of saleable yield within individual primals, with a greater portion produced from the hindquarter relative to the forequarter, specifically in those muscles of the round (P < 0.05). Beta-agonists increased saleable yield, but these effects were not constant between all major primals. The cutout value gained by packers as a result of ß-agonist use may be influenced more by reduced fatness and increased absolute weight if musculature is primarily increased in the lower priced cuts of the carcass.
Asunto(s)
Agonistas Adrenérgicos beta/metabolismo , Composición Corporal/efectos de los fármacos , Bovinos/fisiología , Carne/análisis , Músculo Esquelético/efectos de los fármacos , Fenetilaminas/metabolismo , Compuestos de Trimetilsililo/metabolismo , Agonistas Adrenérgicos beta/administración & dosificación , Alimentación Animal/análisis , Animales , Dieta/veterinaria , Suplementos Dietéticos/análisis , Implantes de Medicamentos/administración & dosificación , Implantes de Medicamentos/farmacología , Estradiol/administración & dosificación , Estradiol/análogos & derivados , Estradiol/farmacología , Masculino , Fenetilaminas/administración & dosificación , Progesterona/administración & dosificación , Progesterona/farmacología , Acetato de Trembolona/administración & dosificación , Acetato de Trembolona/farmacología , Compuestos de Trimetilsililo/administración & dosificaciónRESUMEN
BACKGROUND: The development of surgical site infection (SSI) following vascular surgery is an important issue for healthcare providers as it has serious implications for both patient morbidity and mortality. METHODS: Five publications were identified using the PubMed online database and search terms 'gentamicin-containing collagen implant' plus 'surgical site infection', 'wound infection' and 'vascular surgery'. RESULTS: The reviewed publications demonstrated that prophylactic use of GCCI in conjunction with standard treatment reduces the SSI rate in patients operated on for femeropopliteal bypass grafting. The prophylactic use of GCCI may also have a role to play in patients at high-risk of infection (e.g. in those with co-morbidities such as obesity) and in high-risk procedures (e.g. surgical revision to correct anastomotic aneurysm or dehiscence). GCCI in conjunction with systemic antibiotics may also be effective in the treatment of wound infections of the groin following vascular reconstruction. CONCLUSION: This review demonstrates that GCCI have a role to play in preventing and treating SSI following vascular reconstruction when used in conjunction with standard treatment approaches. Additional randomised, controlled studies are required to further establish the efficacy and cost-effectiveness of GCCI in vascular surgery.
Asunto(s)
Antibacterianos/uso terapéutico , Colágeno Tipo I/uso terapéutico , Implantes de Medicamentos/uso terapéutico , Gentamicinas/uso terapéutico , Infección de la Herida Quirúrgica/terapia , Injerto Vascular/métodos , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Antibacterianos/farmacología , Profilaxis Antibiótica/métodos , Bacterias/efectos de los fármacos , Estudios de Cohortes , Colágeno Tipo I/administración & dosificación , Implantes de Medicamentos/administración & dosificación , Implantes de Medicamentos/farmacología , Femenino , Gentamicinas/administración & dosificación , Gentamicinas/farmacología , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Infección de la Herida Quirúrgica/tratamiento farmacológico , Infección de la Herida Quirúrgica/prevención & controlRESUMEN
To avoid the clinical inconvenience of repeated injection of the immune modulator thymopentin (TP5), biodegradable implants comprising a mixed polymer matrix of poly(lactide acid) (PLA) and poly(lactide-co-glycolide acid) (PLGA) were produced using a simple extrusion method. Drug release from these TP5-loaded implants was characterized both in vitro and in vivo. Pharmacodynamic studies were carried out in immunosuppressed rats using the ratio of CD4(+)/CD8(+) cells, determined by flow cytometry, as an index of immunity. The results indicated that the entrapment efficiency of the implants was greater than 98%, but the release rate of TP5 depended on the drug loading. Implants containing less than 10% TP5 showed consistent release over 30 days, with low burst-release both in vitro and in vivo. Improved immunity and survival rates were observed in rats treated by TP5 injection and in rats given middle-to-high dose implants. When the release of TP5 exceeded 0.1 mg/kg body weight/day the CD4(+)/CD8(+) ratios increased in the 3 weeks after implantation, reaching a maximum (91.6% of the normal level) by the end of the third week. The TP5-loaded implants presented here provide a promising alternative to injections and the results support the further development of controlled-release TP5 formulations.
Asunto(s)
Implantes de Medicamentos/farmacología , Ácido Láctico/farmacología , Poliésteres/farmacología , Ácido Poliglicólico/farmacología , Tecnología Farmacéutica/métodos , Timopentina/farmacología , Animales , Evaluación Preclínica de Medicamentos/métodos , Implantes de Medicamentos/química , Ácido Láctico/química , Masculino , Poliésteres/química , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Timopentina/químicaRESUMEN
The aim of this study was to modify the surfaces of superparamagnetic iron oxide nanoparticles (SPION) with pullulan in order to reduce the cytotoxicity and enhance the cellular uptake of the nanoparticles. In this study, we have prepared and characterised the pullulan coated superparamagnetic iron oxide nanoparticles (Pn-SPION) of size around 40-45 nm with magnetite inner core and hydrophilic outer shell of pullulan. We have investigated the effect of cellular uptake of uncoated and Pn-SPION on cell adhesion/viability, cytotoxicity, morphology and cytoskeleton organisation of human fibroblasts. Cell cytotoxicity/adhesion studies of SPIONs on human dermal fibroblasts showed that the particles are toxic and their internalisation resulted in disruption of cytoskeleton organisation of cells. On the other hand, Pn-SPIONs were found to be non-toxic and induced changes in cytoskeleton organisation different from that observed with SPION. Transmission electron microscopy results indicated that the SPION and Pn-SPION were internalised into cells via different mechanisms, thereby suggesting that the particle endocytosis behaviour is dependent on the surface characteristics of the nanoparticles.
Asunto(s)
Implantes de Medicamentos/farmacología , Endocitosis/fisiología , Compuestos Férricos/farmacología , Fibroblastos/citología , Fibroblastos/fisiología , Glucanos/farmacología , Nanotubos/efectos adversos , Apoptosis/efectos de los fármacos , Línea Celular , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Materiales Biocompatibles Revestidos/efectos adversos , Materiales Biocompatibles Revestidos/farmacología , Citoesqueleto/efectos de los fármacos , Citoesqueleto/fisiología , Citoesqueleto/ultraestructura , Implantes de Medicamentos/efectos adversos , Endocitosis/efectos de los fármacos , Compuestos Férricos/efectos adversos , Fibroblastos/efectos de los fármacos , Glucanos/química , Humanos , Magnetismo/uso terapéutico , Ensayo de Materiales , Nanotubos/químicaRESUMEN
BACKGROUND: Fasting and diabetes are characterized by elevated glucocorticoids and reduced insulin, leptin, elevated hypothalamic AGRP and NPY mRNA, and reduced hypothalamic POMC mRNA. Although leptin replacement can reverse changes in hypothalamic gene expression associated with fasting and diabetes, leptin also normalizes corticosterone; therefore the extent to which the elevated corticosterone contributes to the regulation of hypothalamic gene expression in fasting and diabetes remains unclear. To address if elevated corticosterone is necessary for hypothalamic responses to fasting and diabetes, we assessed the effects of adrenalectomy on hypothalamic gene expression in 48-hour-fasted or diabetic mice. To assess if elevated corticosterone is sufficient for the hypothalamic responses to fasting and diabetes, we assessed the effect of corticosterone pellets implanted for 48 hours on hypothalamic gene expression. RESULTS: Fasting and streptozotocin-induced diabetes elevated plasma glucocorticoid levels and reduced serum insulin and leptin levels. Adrenalectomy prevented the rise in plasma glucocorticoids associated with fasting and diabetes, but not the associated reductions in insulin or leptin. Adrenalectomy blocked the effects of fasting and diabetes on hypothalamic AGRP, NPY, and POMC expression. Conversely, corticosterone implants induced both AGRP and POMC mRNA (with a non-significant trend toward induction of NPY mRNA), accompanied by elevated insulin and leptin (with no change in food intake or body weight). CONCLUSION: These data suggest that elevated plasma corticosterone mediate some effects of fasting and diabetes on hypothalamic gene expression. Specifically, elevated plasma corticosterone is necessary for the induction of NPY mRNA with fasting and diabetes; since corticosterone implants only produced a non-significant trend in NPY mRNA, it remains uncertain if a rise in corticosterone may be sufficient to induce NPY mRNA. A rise in corticosterone is necessary to reduce hypothalamic POMC mRNA with fasting and diabetes, but not sufficient for the reduction of hypothalamic POMC mRNA. Finally, elevated plasma corticosterone is both necessary and sufficient for the induction of hypothalamic AGRP mRNA with fasting and diabetes.
Asunto(s)
Diabetes Mellitus Experimental/fisiopatología , Ayuno/fisiología , Regulación de la Expresión Génica/fisiología , Glucocorticoides/fisiología , Hipotálamo/fisiología , Hipotálamo/fisiopatología , Médula Suprarrenal/fisiología , Médula Suprarrenal/fisiopatología , Médula Suprarrenal/cirugía , Adrenalectomía/métodos , Proteína Relacionada con Agouti , Animales , Corticosterona/administración & dosificación , Corticosterona/farmacología , Diabetes Mellitus Experimental/sangre , Implantes de Medicamentos/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Glucocorticoides/sangre , Hipotálamo/efectos de los fármacos , Insulina/deficiencia , Insulina/genética , Insulina/fisiología , Péptidos y Proteínas de Señalización Intercelular , Leptina/genética , Masculino , Ratones , Ratones Endogámicos C57BL , Neuropéptido Y/genética , Proopiomelanocortina/genética , Proteínas/genética , ARN Mensajero/genética , ARN Mensajero/metabolismoRESUMEN
Norplant is a new method of birth control recently approved for use in the United States. It consists of flexible Silastic capsules filled with levonorgestrel, which are inserted subdermally on the inside of the upper arm. Norplant provides a near steady-state level of levonorgestrel for five years. It has been used in many European, South American and Asian countries, and in clinical studies in the United States. Norplant has an excellent continuation rate by users, and it is highly effective. It causes minimal adverse effects other than irregular menstrual patterns.